Computer-aided drug screening of anti-Neobenedenia melleni drugs based on annexin B1 in farmed pearl grouper
Longkun Gao, Wei LuoiD, Yanru GuoiD, Ying Yan, Guanhai Li, Qin Yu, Mingzhu LiuiD, Erlong Wang, Pengfei LiiD, Tianqiang LiuiD
Abstract
Monogenean capsalids of the genus Neobenedenia are widespread parasites of wild and farmed marine fish, and represent a great threat to the mariculture of grouper in China. Fishery drug development to screen and find effective compounds to control and prevent the disease is urgent needed, considering the vast production of grouper in China (294 ktons in 2025). Annexins have been discovered in Neobenedenia and other parasites, and marked differences between the parasite annexins and those of the hosts make them potentially attractive drug targets for anti-parasite therapeutics. Herein, we utilized computer-based drug discovery screens using unique Neobenedenia melleni annexin B1 and a database of 1,456,161 small molecules. The 3D structure of annexin B1 was firstly modeled by three different protein prediction tools, namely AlphaFold 3, SWISS-MODEL, and I-TASSER, of which the most accurate protein structure was used as the drug target for the following structure-based virtual screening. In vivo experimental validation of 11 compounds after molecular docking shows that abamectin (Aba) has the most effective anti-Neobenedenia bioactivity at the concentration of 0.16 mg/L as the initial screening concentration. Given its low toxicity to host grouper (24 LC50=0.254 mg/L), abamectin was chose for further investigation. A 24 h bath exposure successfully lowered the parasitic load in infected grouper, yielding an 24 h EC50 of 0.033 mg. To elucidate the anti-parasite mechanism, long-timescale molecular dynamics simulations (1000 ns) of annexin B1 and Aba was conducted, which allowed for atomic and molecular-level analysis of the essential protein motions involved in the interaction of annexin B1 and its substrate. The interaction profile between annexin B1 and abamectin was dominated by hydrophobic contacts and water bridges, involving residues TYR-210, GLU-214, GLU-244, and SER-247, which path a way for further drug optimization.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In Vivo Screening for a Promising Antiparasitic Agent Against Neobenedenia melleni in Epinephelus fuscoguttatusfemale x E. lanceolatusmale and Identification of Its Potential Target
Longkun Gao, Guangshuo Wang, … Tianqiang Liu·bioRxiv·Aug 25, 2026
- Repurposing drugs to treat Amoebic Gill Disease in Atlantic Salmon
Yee Wan Liu, Abby L. E. Bryce, … Martin Stephen Llewellyn·bioRxiv·Jun 7, 2026
- Discovery of anti-amoebic inhibitors from screening the MMV Pandemic Response Box on Balamuthia mandrillaris, Naegleria fowleri and Acanthamoeba castellanii
C. A. Rice, E. V. Troth, … D. E. Kyle·bioRxiv·May 14, 2020
- Screening the Medicines for Malaria Pandemic Response Box chemical library on Caenorhabditis elegans identifies re-profiled candidate anthelmintic drug leads
M. Nick, F. A. Partridge, … D. B. Sattelle·bioRxiv·Aug 10, 2022
- Nementin is a Nematode-Selective Small Molecule Agonist of Neurotransmitter Release
S. Harrington, J. J. Knox, … P. Roy·bioRxiv·Mar 12, 2022
- AgamOBP4-targeted drug repurposing identifies novel mosquito repellent scaffolds
Jorge-Ricardo Alonso-Fernández, Evgenia C.V. Stamati, … Katerina E. Tsitsanou·bioRxiv·Oct 22, 2026